← Back to patent-cliff list
Angiotensin II
Tier C — Watch / tradeAngiotensin II
La Jolla Pharma
Originator
2017
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AT2
Brand：Giapreza
Indications (approved)：Hypotension, Shock
Regional status
US
Approved
2017-12-21
EU
Approved
2019-08-23
China
Phase III
2024-07-23
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Angiotensin II?
Approved indications include: Hypotension, Shock.
When does the Angiotensin II patent expire?
No public expiry year is available for Angiotensin II yet; this page updates once verified.
How do I get a quote for Angiotensin II intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29